22SCH740: Phase II Study of Estradiol Therapy to Target ER-Mutant and ER-Wild-Type ER+ Metastatic or Advanced Breast Cancer (ESTHER)
Principal Investigator
Study Number
STUDY02001740
Summary
This study is for post-menopausal patients with ER+ breast cancer that has either spread to other parts of the body or come back in the same place while taking hormone therapy. The usual treatment for this type of cancer is hormone blocking agents or chemotherapy. Participants in this study will instead take estradiol, an estrogen hormone that naturally occurs in humans. It is approved by the U.S. Food and Drug Administration (FDA) to treat breast cancer. The purpose of this study is to learn how effective estradiol is at treating ER+ breast cancers, and whether specific types of ER+ breast cancer may respond better to treatment with estradiol than other types of breast cancer.
Phase
II
Contact
Available at the following location(s)
- Lebanon
View more details at ClinicalTrials.gov
Do you need help with some of the labels on this page?
Read our glossary of terms